Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | CTSV | O60911 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209768 | 0.92 | DPP4 (0.39) | DPP4DPP8CTSVCTSSCTSK | |
| Hydrochloric Acid SCHEMBL29609105 | 0.90 | DPP4 (0.38) | DPP4DPP8CTSVCTSSCTSK | |
| Trifluoroacetic Acid SCHEMBL27076720 | 0.89 | DPP4 (0.37) | DPP4DPP8CTSVCTSSCTSK | |
| Trifluoroacetic Acid SCHEMBL30489482 | 0.88 | CTSV (0.37) | DPP4DPP8CTSVCTSSCTSK | |
| SCHEMBL27076715 | 0.85 | DPP4 (0.34) | DPP4DPP8CTSVCTSSCTSK | |
| SCHEMBL26119474 | 0.81 | DPP4 (0.40) | DPP4DPP8CTSVCTSSCTSK | |
| SCHEMBL24425133 | 0.81 | DPP4 (0.40) | DPP4DPP8CTSVCTSSCTSK | |
| SCHEMBL25135486 | 0.80 | DPP4 (0.40) | DPP4DPP8CTSVCTSSCTSK | |
| SCHEMBL7724507 | 0.80 | DPP4 (0.40) | DPP4DPP8CTSVCTSSCTSK | |
| SCHEMBL8188346 | 0.80 | DPP4 (0.40) | DPP4DPP8CTSVCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| EP-4313305-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208113-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | ACE2, SARS1, ACE | DPP4 88/4885DPP8 585/4885CTSV 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.